Compare Cassava Sciences Inc (FLNA) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kyndryl Holdings Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Kyndryl Holdings Inc trades at $11.76 (market cap $2.49B). The key difference: Kyndryl Holdings Inc is far larger — about 63.2× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 4,191,904). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Kyndryl Holdings Inc for 36 Days on average.
| FLNA | KD | |
|---|---|---|
Market Cap | $39.40M | $2.49B |
Volume | 759,018 | 4,191,904 |
Sector | Health | Technology |
52-Week High | $4.64 | $29.76 |
52-Week Low | $0.68 | $10.59 |
Typical Hold Time | 37 Days | 36 Days |
Enterprise Value | -$43.28M | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Kyndryl (KD) trades at $11.88, up 3.48% today, with a bearish technical signal and mixed earnings. Revenue declined to $15.06B in 2025, but net income turned positive at $252M, marking a recovery from prior losses. The company is actively investing in AI, as highlighted by recent news of an AI innovation lab and acquisitions. Analyst consensus is mostly hold, with a $14.67 price target suggesting moderate upside.
The outlook hinges on AI-driven growth offsetting revenue pressures, but risks include high debt, competitive IT services market, and inconsistent earnings. Institutional sentiment is cautious, with weak technical trends near key support. Upside depends on execution of modernization contracts and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
